Personalized Treatment Outcomes
UroMe.ai uses AI technology to rapidly bring the benefits of organoids to every patient with Bladder Cancer
- Organoid Technology
We generated a biobank of patient-derived Bladder Cancer organoids in which we test treatment response to all approved medical treatments for Bladder Cancer. We are also collecting molecular and clinical data from for each patient.
- Growing Dataset.
We are continuously growing our organoid-based biobank and are looking for partners to assist us in our quest to personalize Bladder Cancer treatment.
- AI-Based Decision
We developed an algorithm that can predict treatment response in patients with Bladder Cancer based on treatment response data generated in organoids as well as clinical and molecular information. The algorithm allows clinicians to use the benefits of organoids without the need to generate them for each individual patient; which may take months before getting a result.
UroMe.ai Supports Clinicians in Their Decision
Our algorithm provides clinicians with a probability of treatment success to help them make a rapid and personalized treatment decision.
- Organoid.
- Organoids are tumor tissue-derived biological twins of each patient with Bladder Cancer.
- Effective Responses.
- We test responses to multiple treatments in parallel in organoids to estimate which treatment would be most effective for each patient.
- Data
- We are collecting an extensive set of molecular and clinical data for each patient.
